Lista de obras -

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

artículo científico publicado en 2011

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

artículo científico publicado en 2011

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer

artículo científico publicado en 2006

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

artículo científico publicado en 2008

Chemoradiation in the management of esophageal cancer

artículo científico publicado en 2007

Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization

artículo científico publicado en 2007

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

artículo científico publicado en 2013

Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study

artículo científico publicado en 2013

Combined-modality therapy for esophageal cancer: are we making progress?

artículo científico publicado en 2003

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

artículo científico publicado en 2010

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

artículo científico publicado en 2011

HPV-associated head and neck cancer: a virus-related cancer epidemic

artículo científico publicado en 2010

Impact of surgeon and hospital volume on short‐term outcomes and cost of oropharyngeal cancer surgical care ⬇️

artículo científico publicado el 1 de abril de 2011

Is open surgery for head and neck cancers truly declining?

artículo científico publicado en 2013

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck

artículo científico publicado en 2012

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer

artículo científico publicado en 2012

Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus

artículo científico publicado en 2008

Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art.

artículo científico publicado en 2004

Neck dissection followed by radiotherapy or chemoradiotherapy for small primary oropharynx carcinoma with cervical metastasis

artículo científico publicado en 2005

Organ preservation for cancer of the larynx: current indications and future directions

artículo científico publicado en 2004

Organ preservation trials for laryngeal cancer

artículo científico publicado en 2002

Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.

artículo científico publicado en 2016

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy

artículo científico publicado en 2004

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.

artículo científico publicado en 2015

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcino

artículo científico publicado en 2012

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2004

Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

artículo científico publicado en 2014

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

artículo científico publicado en 2005

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

artículo científico publicado en 2013

Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

artículo científico publicado en 2014

Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature

artículo científico publicado en 2019

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

artículo científico publicado en 2014

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2005

Reassessment of the role of induction chemotherapy for head and neck cancer

artículo científico publicado en 2006

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

artículo científico publicado en 2009

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

artículo científico publicado en 2017

Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial

artículo científico publicado en 2007

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

artículo científico publicado en 2007

The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins

artículo científico publicado en 2009

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)

artículo científico publicado en 2020

When is chemotherapy in head and neck squamous cell carcinoma not indicated?

artículo científico publicado en 2014

Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma

artículo científico publicado el 7 de diciembre de 2012

Lista de obras de

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

Chemoradiation in the management of esophageal cancer

Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study

Combined-modality therapy for esophageal cancer: are we making progress?

Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

HPV-associated head and neck cancer: a virus-related cancer epidemic

Impact of surgeon and hospital volume on short‐term outcomes and cost of oropharyngeal cancer surgical care ⬇️

Is open surgery for head and neck cancers truly declining?

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer

Modeling using baseline characteristics in a small multicenter clinical trial for Barrett's esophagus

Multidisciplinary approaches in the management of advanced head and neck tumors: state of the art.

Neck dissection followed by radiotherapy or chemoradiotherapy for small primary oropharynx carcinoma with cervical metastasis

Organ preservation for cancer of the larynx: current indications and future directions

Organ preservation trials for laryngeal cancer

Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy

Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic.

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcino

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group

Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303.

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial

Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

Reassessment of the role of induction chemotherapy for head and neck cancer

Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.

Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins

Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOG-ACRIN Cancer Research Group (E1302)

When is chemotherapy in head and neck squamous cell carcinoma not indicated?

Chemoradiotherapy vs. total laryngectomy for primary treatment of advanced laryngeal squamous cell carcinoma